{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:11:21Z","timestamp":1778721081541,"version":"3.51.4"},"reference-count":18,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"AoP","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2024,8,25]]},"abstract":"<jats:p>Aim: To retrospectively evaluate the anatomical and functional success of surgical treatment of rhegmatogenous retinal detachment (RRD) in the only remaining seeing eye.\n\nMaterial and methods: The study included 28 eyes of 28 patients, 19 (68%) of whom were men, with an average age of 46 years. They were operated on by a single surgeon for RRD at the Eye Clinic of the University Hospital and Faculty of Medicine, Masaryk University in Brno, from July 1, 2019, to April 30, 2023, using cryosurgical techniques and\/or 25G+ pars plana vitrectomy (PPV). In 11 patients, 25G+ PPV was performed with the application of a pre-equatorial cerclage. The Blunt ocular trauma and uncomplicated cataract surgery with implantation of a posterior chamber intraocular lens were admissible within the patient histories. The cause of RRD was retinal tear(s) regardless of their number and location. The transparency of the anterior segment of the eye enabled reliable visualization of the posterior segment. Preoperative proliferative vitreoretinopathy (PVR) grades A-D2 were acceptable. Patients with a history of penetrating eye injury were excluded. Patients were evaluated 1-3 months after the performance of PPV. The surgery was considered anatomically successful if the retina was completely reattached. Each patient's final visual acuity (VA) was assessed using a Snellen chart. Numerical results were expressed as arithmetic means and percentages. Since the different groups were not compared, no statistical tests were needed.\n\nResults: Retinal reattachment was achieved in 27 patients (97%), while 1 patient (3%) experienced retinal detachment, resulting in anatomical failure of the treatment. 9 patients (32%) achieved VA \u2265 4\/8.\n\nConclusion: We consider cryosurgical techniques using episclerally fixed cerclage bands and buckles, 25G+ PPV, and possibly a combination thereof, to be suitable methods for treating RRD in the only remaining seeing eye.<\/jats:p>","DOI":"10.31348\/2024\/38","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:44:31Z","timestamp":1737470671000},"source":"Crossref","is-referenced-by-count":1,"title":["Surgical Treatment of Rhegmatogenous Retinal Detachment in the Only Seeing Eye"],"prefix":"10.31348","author":[{"given":"Old\u0159ich","family":"Chrapek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Matu\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Vyslou\u017eilov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sou\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krist\u00edna","family":"Si\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"B\u0159ez\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2024,8,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9-vention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051\/medsci\/2020163","DOI":"10.1051\/medsci\/2020163"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"de las Rivas Ram\u00edrez N, Luque Aranda G, Rius D\u00edaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977.","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current tre-atment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345\/cep.2021.00773","DOI":"10.3345\/cep.2021.00773"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Thi-rd Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016\/j.ophtha.2021.05.031","DOI":"10.1016\/j.ophtha.2021.10.021"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmo-logists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Gui-delines. Ear-ly Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016\/j.earlhumdev.2023.105715","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"ref5","unstructured":"Kanski\u2019s Clinical Ophtalmology 2020; p.538."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Ear-ly Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520.","DOI":"10.1093\/med\/9780190050726.003.0027"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zobanov\u00e1 A, Brychc\u00ednov\u00e1 P, Autrata R, \u0160enkov\u00e1 K. Screening, Treatment and Long-term Observa-tion of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264.","DOI":"10.31348\/2018\/6\/7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103\/sjopt.sjopt_18_22","DOI":"10.4103\/sjopt.sjopt_18_22"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prema-turity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038\/s41372-021-01015-8","DOI":"10.1038\/s41372-021-01015-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in pre-mature, extremely low birth weight and extremely low gestational age infants. BMC Ophthal-mol. 2022 Sep 13;22(1):367. doi: 10.1186\/s12886-022-02591-9","DOI":"10.1186\/s12886-022-02591-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Tre-atment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Coun-tries. Pedi-atric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147\/PHMT.S391591","DOI":"10.2147\/phmt.s391591"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Reti-nopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097\/APO.0000000000000302","DOI":"10.1097\/apo.0000000000000302"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Re-cent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542\/peds.2021-053924. PMID: 35948728","DOI":"10.1542\/peds.2021-053924"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301\/ejo.5000166","DOI":"10.5301\/ejo.5000166"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american asso-ciation of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prema-turity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542\/peds.2018-3061. Erratum in: Pe-diatrics. 2019 Mar;143(3)","DOI":"10.1542\/peds.2018-3810"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016\/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213","DOI":"10.1016\/j.ajo.2020.12.018"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389\/fphar.2022.897869","DOI":"10.3389\/fphar.2022.897869"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:44:34Z","timestamp":1737470674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":18,"journal-issue":{"issue":"AoP","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.31348\/2024\/38","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"value":"1805-4447","type":"electronic"},{"value":"1211-9059","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,25]]}}}